{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-068985","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.837733+00:00","generated_at":"2026-06-22T09:30:21.103684+00:00","sec_items":["1.01","3.02","5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Hoth Therapeutics issues 2M shares of Series B Preferred with 10-to-1 voting for $1,000","bullets":["Sold 2,000,000 Series B Preferred shares to a single investor for aggregate $1,000; shares have $0.0001 par value.","Each Series B share carries 10 votes, voting only on Authorized Stock Increase; no dividend or liquidation rights.","Series B Preferred automatically redeemed for $10 upon effectiveness of Authorized Stock Increase or at board's discretion.","Shares issued in unregistered transaction relying on Section 4(a)(2) exemption.","Certificate of Designation filed in Nevada to create the new series."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-068985","json":"https://secwatch.observer/filing/0001213900-22-068985.json","markdown":"https://secwatch.observer/filing/0001213900-22-068985.md","text":"https://secwatch.observer/filing/0001213900-22-068985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390022068985/0001213900-22-068985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390022068985/ea167990-8k_hoththera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:30:21.103684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f12f62ffd2e0fcd6610aea9dc9bbe6603610b3f1","claim":"Hoth Therapeutics, Inc.: Created Series B Preferred Stock, designating 2,000,000 shares (effective 2022-11-02).","evidence_excerpt":"On November 2, 2022, the Company filed a Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to create a new class of Series B Preferred Stock, par value $0.0001 per share.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390022068985/0001213900-22-068985-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2022-11-02"}],"fact_type":"governance_change"},{"claim_id":"01763d869bac58024921e8d05cc520c8889ce65f","claim":"Hoth Therapeutics, Inc. entered into Subscription Agreement with an investor valued at $1,000 (effective 2022-11-02).","evidence_excerpt":"On November 2, 2022, Hoth Therapeutics, Inc. (the “Company”) entered into a Subscription and Investment Representation Agreement (the “Subscription Agreement”) with an investor (the “Purchaser”) pursuant to which it issued and sold 2,000,000 shares (the “Shares”) of the Company’s newly designated Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), to such Purchaser for an aggregate purchase price of $1,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711786/000121390022068985/0001213900-22-068985-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor"},{"label":"Value","value":"$1,000"},{"label":"Effective","value":"2022-11-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}